Resources from the same session
Introduction
Presenter: Christopher Booth
Session: How does real-world evidence inform decision making for new drug funding?
Resources:
Webcast
The limitations of clinical evidence from trials when data presented for HTA: Immature survival data, selected patient populations, phase II data for uncommon cancers etc...
Presenter: Nathan Cherny
Session: How does real-world evidence inform decision making for new drug funding?
Resources:
Slides
Webcast
RWE: When should it be used by EMA?
Presenter: Francesco Pignatti
Session: How does real-world evidence inform decision making for new drug funding?
Resources:
Slides
Webcast
Challenges of collecting RWE: Limitations of administrative data sets, complex methodological issues, responsibility for collecting data
Presenter: Valery Lemmens
Session: How does real-world evidence inform decision making for new drug funding?
Resources:
Slides
Webcast